Early prediction of pathologic response to neoadjuvant therapy in breast cancer: systematic review of the accuracy of MRI.

Magnetic resonance imaging (MRI) has been proposed to have a role in predicting final pathologic response when undertaken early during neoadjuvant chemotherapy (NAC) in breast cancer. This paper examines the evidence for MRI's accuracy in early response prediction. A systematic literature search (to February 2011) was performed to identify studies reporting the accuracy of MRI during NAC in predicting pathologic response, including searches of MEDLINE, PREMEDLINE, EMBASE, and Cochrane databases. 13 studies were eligible (total 605 subjects, range 16-188). Dynamic contrast-enhanced (DCE) MRI was typically performed after 1-2 cycles of anthracycline-based or anthracycline/taxane-based NAC, and compared to a pre-NAC baseline scan. MRI parameters measured included changes in uni- or bidimensional tumour size, three-dimensional volume, quantitative dynamic contrast measurements (volume transfer constant [Ktrans], exchange rate constant [k(ep)], early contrast uptake [ECU]), and descriptive patterns of tumour reduction. Thresholds for identifying response varied across studies. Definitions of response included pathologic complete response (pCR), near-pCR, and residual tumour with evidence of NAC effect (range of response 0-58%). Heterogeneity across MRI parameters and the outcome definition precluded statistical meta-analysis. Based on descriptive presentation of the data, sensitivity/specificity pairs for prediction of pathologic response were highest in studies measuring reductions in Ktrans (near-pCR), ECU (pCR, but not near-pCR) and tumour volume (pCR or near-pCR), at high thresholds (typically >50%); lower sensitivity/specificity pairs were evident in studies measuring reductions in uni- or bidimensional tumour size. However, limitations in study methodology and data reporting preclude definitive conclusions. Methods proposed to address these limitations include: statistical comparison between MRI parameters, and MRI vs other tests (particularly ultrasound and clinical examination); standardising MRI thresholds and pCR definitions; and reporting changes in NAC based on test results. Further studies adopting these methods are warranted.

[1]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[2]  Sarah Lord,et al.  When Is Measuring Sensitivity and Specificity Sufficient To Evaluate a Diagnostic Test, and When Do We Need Randomized Trials? , 2006, Annals of Internal Medicine.

[3]  G. Hortobagyi,et al.  Can early response assessment guide neoadjuvant chemotherapy in early-stage breast cancer? , 2008, Journal of the National Cancer Institute.

[4]  S. Rodenhuis,et al.  Magnetic resonance imaging response monitoring of breast cancer during neoadjuvant chemotherapy: relevance of breast cancer subtype. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  A. Schneeweiss,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: new perspectives 2006. , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[6]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Kenneth G A Gilhuijs,et al.  Dynamic contrast-enhanced MRI for prediction of breast cancer response to neoadjuvant chemotherapy: initial results. , 2008, AJR. American journal of roentgenology.

[8]  M. Tozaki,et al.  Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method , 2010, Journal of magnetic resonance imaging : JMRI.

[9]  Thomas E. Yankeelov,et al.  Current and Future Trends in Magnetic Resonance Imaging Assessments of the Response of Breast Tumors to Neoadjuvant Chemotherapy , 2010, Journal of oncology.

[10]  A. Luini,et al.  Pathological complete response after preoperative systemic therapy and outcome: relevance of clinical and biologic baseline features , 2010, Breast Cancer Research and Treatment.

[11]  P. Bossuyt,et al.  BMC Medical Research Methodology , 2002 .

[12]  Roberto Orecchia,et al.  Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. , 2010, European journal of cancer.

[13]  Hon J. Yu,et al.  Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. , 2009, Radiology.

[14]  S. Loibl,et al.  Neoadjuvant vinorelbine-capecitabine versus docetaxel-doxorubicin-cyclophosphamide in early nonresponsive breast cancer: phase III randomized GeparTrio trial. , 2008, Journal of the National Cancer Institute.

[15]  Carmel Hayes,et al.  Prediction of clinicopathologic response of breast cancer to primary chemotherapy at contrast-enhanced MR imaging: initial clinical results. , 2006, Radiology.

[16]  D. Bluemke,et al.  Multiparametric magnetic resonance imaging, spectroscopy and multinuclear (²³Na) imaging monitoring of preoperative chemotherapy for locally advanced breast cancer. , 2010, Academic radiology.

[17]  Peter Gibbs,et al.  Diffusion changes precede size reduction in neoadjuvant treatment of breast cancer. , 2006, Magnetic resonance imaging.

[18]  Jun Li,et al.  Quantitative analysis of clinical dynamic contrast-enhanced MR imaging for evaluating treatment response in human breast cancer. , 2010, Radiology.

[19]  Daniele Regge,et al.  Monitoring Response to Primary Chemotherapy in Breast Cancer using Dynamic Contrast-enhanced Magnetic Resonance Imaging , 2004, Breast Cancer Research and Treatment.

[20]  B. Naume,et al.  Neoadjuvant chemotherapy in breast cancer-response evaluation and prediction of response to treatment using dynamic contrast-enhanced and diffusion-weighted MR imaging , 2010, European Radiology.

[21]  P. Fasching,et al.  Correlation of various pathologic complete response (pCR) definitions with long-term outcome and the prognostic value of pCR in various breast cancer subtypes: Results from the German neoadjuvant meta-analysis. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  I. Makhoul,et al.  Neoadjuvant systemic treatment of breast cancer , 2011, Journal of surgical oncology.

[23]  C Gatsonis,et al.  Validation of novel imaging methodologies for use as cancer clinical trial end-points. , 2009, European journal of cancer.

[24]  Johannes B Reitsma,et al.  Evaluation of QUADAS, a tool for the quality assessment of diagnostic accuracy studies , 2006, BMC medical research methodology.

[25]  Andreas Makris,et al.  Early Changes in Functional Dynamic Magnetic Resonance Imaging Predict for Pathologic Response to Neoadjuvant Chemotherapy in Primary Breast Cancer , 2008, Clinical Cancer Research.

[26]  A. Schneeweiss,et al.  S3-2: Neoadjuvant Chemotherapy Adapted by Interim Response Improves Overall Survival of Primary Breast Cancer Patients - Results of the GeparTrio Trial. , 2011 .

[27]  S. Sener,et al.  Neoadjuvant therapy for breast cancer , 2010, Journal of surgical oncology.

[28]  F. Sardanelli,et al.  Breast MRI using a high-relaxivity contrast agent: an overview. , 2011, AJR. American journal of roentgenology.

[29]  T. Taguchi,et al.  Good Response to Paclitaxel Predicts High Rates of Pathologic Complete Response for Breast Cancer Patients Treated Preoperatively with Paclitaxel Followed by 5-Fluorouracil, Epirubicin and Cyclophosphamide , 2008, Oncology.

[30]  T. Churches A proposed architecture and method of operation for improving the protection of privacy and confidentiality in disease registers , 2003, BMC medical research methodology.

[31]  J. Bryant,et al.  Preoperative chemotherapy in patients with operable breast cancer: nine-year results from National Surgical Adjuvant Breast and Bowel Project B-18. , 2001, Journal of the National Cancer Institute. Monographs.

[32]  D. Narayanan,et al.  Breast cancer: comparative effectiveness of positron emission mammography and MR imaging in presurgical planning for the ipsilateral breast. , 2011, Radiology.

[33]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.

[34]  L. Walker,et al.  Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. , 2002, Clinical breast cancer.

[35]  D. Collins,et al.  Primary human breast adenocarcinoma: imaging and histologic correlates of intrinsic susceptibility-weighted MR imaging before and during chemotherapy. , 2010, Radiology.

[36]  N. deSouza,et al.  Functional magnetic resonance: biomarkers of response in breast cancer , 2011, Breast Cancer Research.

[37]  F. Penault-Llorca,et al.  Prognostic significance of a complete pathological response after induction chemotherapy in operable breast cancer , 2002, British Journal of Cancer.

[38]  B. Corcioni,et al.  Contrast-enhanced US and MRI for assessing the response of breast cancer to neoadjuvant chemotherapy(). , 2008, Journal of ultrasound.

[39]  M. Meunier,et al.  MRI for surgical planning in patients with breast cancer who undergo preoperative chemotherapy. , 2004, AJR. American journal of roentgenology.

[40]  J E Husband,et al.  Evaluation of the response to treatment of solid tumours – a consensus statement of the International Cancer Imaging Society , 2004, British Journal of Cancer.

[41]  Sibel Kul,et al.  Contrast-enhanced MR angiography of the breast: Evaluation of ipsilateral increased vascularity and adjacent vessel sign in the characterization of breast lesions. , 2010, AJR. American journal of roentgenology.

[42]  Fiona J Gilbert,et al.  Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.